Exact Sciences Says FDA Approves Exact Sciences' Cologuard Plus Test, Setting New Benchmark In Non-Invasive Colorectal Cancer Screening, Company Expects To Launch Cologuard Plus Test With Medicare Coverage And Guideline Inclusion In 2025
Portfolio Pulse from Nabaparna Bhattacharya
Exact Sciences announced that the FDA has approved its Cologuard Plus test, a new benchmark in non-invasive colorectal cancer screening. The company plans to launch the test with Medicare coverage and guideline inclusion in 2025.
October 04, 2024 | 10:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Exact Sciences' Cologuard Plus test has received FDA approval, marking a significant advancement in non-invasive colorectal cancer screening. The company plans to launch the test in 2025 with Medicare coverage and guideline inclusion.
The FDA approval of Cologuard Plus is a major milestone for Exact Sciences, likely boosting investor confidence and potentially increasing the company's market share in the colorectal cancer screening market. The planned launch with Medicare coverage in 2025 further strengthens its market position.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100